Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast CancerPaula I. González-Ericsson, Emanuel Petricoin, Kim Blenman et al.|Clinical Cancer Research|2021Cited by 92
Abstract 5248: The use of reverse phase protein array (RPPA) to identify new tumor vulnerability and actionable drug targets against human cancer cell linesAndrew Howell, Amy Tang, Julia D. Wulfkhule et al.|Cancer Research|2023Cited by 0
Abstract B077: Subtype-specific signaling dynamics during treatment in non-responding breast cancer patients in the neoadjuvant I-SPY2 TRIAL: are there clues on how to overcome resistance?Denise M. Wolf, Laura van ‘t Veer, Christina Yau et al.|Cancer Research|2024Cited by 0
Data from Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast CancerPaula I. González-Ericsson, Justin M. Balko, Julia D. Wulfkhule et al.|Unknown|2024Cited by 0
Supplementary Methods, Supplementary Table 1-4 and Supplementary Figure legends from Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast CancerPaula I. González-Ericsson, Justin M. Balko, Julia D. Wulfkhule et al.|Unknown|2024Cited by 0